SCHEMBL4137625

SCHEMBL4137625

CSc1ccccc1/C=C1\SC(=S)N(Cc2ccc3c(c2)OCO3)C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.62
▸ KMT2A Q03164 9/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ PKM P14618 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ MEN1 O00255 8/20 0.47
▸ NSD2 O96028 1/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ APOBEC3G Q9HC16 1/20 0.47
▸ CTRC Q99895 2/20 0.46
▸ CMA1 P23946 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ ALOX12 P18054 2/20 0.45
▸ RECQL P46063 2/20 0.45
▸ MCL1 Q07820 1/20 0.45
▸ DDX3X O00571 1/20 0.44
▸ POLB P06746 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4137628 1.00 MAPK1 (0.62) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4016080 0.85 MAPK1 (0.65) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4138004 0.85 MAPK1 (0.65) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4138006 0.85 MAPK1 (0.65) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4016078 0.85 MAPK1 (0.65) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4014803 0.85 MAPK1 (0.65) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4133327 0.85 MAPK1 (0.62) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4133333 0.85 MAPK1 (0.62) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4133330 0.85 MAPK1 (0.62) MAPK1KMT2ASMN1; SMN2PKMTSHR
SCHEMBL4148317 0.83 MAPK1 (0.65) MAPK1KMT2ASMN1; SMN2PKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247516-A1 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS KOTNIK MIHA 2009-10-01 — — US disclosed
US-20090247516-A1 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS KOTNIK MIHA 2009-10-01 — — US disclosed
EP-1916249-A1 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents LEK Pharmaceuticals D.D. (SI) 2008-04-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247516-A1 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS XDH, TXLNA, Q6ZSR9 MAPK1 3035/4885KMT2A 1459/4885SMN1; SMN2 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback